1. R.
Green and K.J. Widder, Methods in Enzymology (Academic Press, San Diego, 1987),
p. 149.
2. C.
Ropars, M. Chassaigne, and C. Nicoulau, Advances in the BioSciences, (Pergamon
Press, Oxford, 1987), p. 67.
3. D.A.
Lewis and H.O. Alpar, “Therapeutic Possibilities of Drugs Encapsulated in
Erythrocytes,” Int J. Pharm. 22, 137–146 (1984).
4. D.A.
Lewis and H.O. Alpar, “Therapeutic Possibilities of Drugs Encapsulated in
Erythrocytes,” Int. J. Pharm. 22, 137–146 (1984).
5. TV
Thulasiramaraju, A Arunachalam, GV Surendra babu, N Syamkumar, VV Nagendra
babu, M Nikilesh babu, International Journal of Preclinical and Pharmaceutical
Research, 2011, 3-13.
6. L
Rossi, Expert Opin. Drug delivery, 2005, 2, 311-322.
7. M
Magnani, Gene Ther, 2002, 11, 749-751.
8. VS
Gopal, RC Doijad, PB Deshpande, Pak J. Pharm. Sci, 2010, 23, 194-200.
9. KK
Sawant, HN Soni, RSR Murthy, Indian J. Pharm. Sci, 2001, 63, 105-109.
10. AK
Shah, A Rambhade, A Ram, SKJ ain, Journal of chemical & pharmaceutical research,
2011, 3(2).
11. Sockolosky,
J. T., &Szoka, F. C. (2015). The neonatal Fc receptor, FcRn, as a target
for drug delivery and therapy. Advanced drug delivery reviews, 91, 109–12.
https://doi.org/10.1016/j.addr.2015.02.005
12. Atukorale,
P. U., Yang, Y. S., Bekdemir, A., Carney, R. P., Silva, P. J., Watson, N.,
Stellacci, F., & Irvine, D. J. (2015). Influence of the glycocalyx and
plasma membrane composition on amphiphilic gold nano- particle association with
erythrocytes. Nanoscale, 7(26), 11420–11432. https://doi.org/10.1039/c5nr01355k
13. Villa,
C. H., Anselmo, A. C., Mitragotri, S., &Muzykantov, V. (2016). Red blood
cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration
for advanced delivery systems. Advanced drug delivery reviews, 106(Pt A),
88–103. https://doi.org/10.1016/j.addr.2016.02.007
14. S.P.
Vyas and R.K. Khar, Resealed Erythrocytes in Targeted and Controlled Drug
Delivery: Novel Carrier Systems (CBS Publishers and Distributors, India, 2002),
pp. 87–416.
15. G.
Gardos, “Akkumulation de Kalium Onen Durch Menschiche Blutkorperchen,” Acta
Physiol. Acad. Sci. Hung 6, 191–196 (1953).
16. G.M.
Iher, R.M. Glew, and F.W. Schnure, “Enzyme Loading of Erythrocytes,” Proc.
Natl. Acad. Sci. USA 70, 2663–2666 (1973).
17. U.
Zimmermann, Jahresbericht der Kernforschungsanlage Julich GmbH (Nuclear
Research Center, Julich, 1973), pp. 55–58.
18. Eletron insertion method:
Pragya,
V Rastogi, International Journal of Pharmacy and Pharmaceutical Sciences, 2012,
4(3), 75-82.
19. M
Hamidi, N Zarei, M Foroozesh, Mohammadi Samani S. J. Control Release, 2007,
118: 145‐160.
20. A
Kumar, M verma, KK Jha, The Pharma Innovation, 2012, 1(2), 7-15.
21. Muldoon,
L. L., Jamieson, G. A., Jr, &Villereal, M. L. (1987). Calcium mobilization
in permeabilized fibroblasts: effects of inositol trisphosphate, orthovanadate,
mitogens, phorbol ester, and guanosine triphosphate. Journal of cellular
physiology, 130(1), 29–36. https://doi.org/10.1002/jcp.1041300106
22. Ihler
GM, Glew RM, Schnure FW. Enzyme loading of erythrocytes. Proc Natl Acad Sci USA
1973
23. Ihler,
G. M., & Tsang, H. C. (1987). Hypotonic hemolysis methods for entrapment of
agents in resealed erythrocytes. Methods in enzymology, 149, 221–229.
https://doi.org/10.1016/0076-6879(87)49059-9
24. Updike,
S. J., &Wakamiya, R. T. (1983). Infusion of red blood cell-loaded
asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.
The Journal of laboratory and clinical medicine, 101(5), 679–691.
25. Adriaenssens,
K., Karcher, D., Lowenthal, A., &Terheggen, H. G. (1976). Use of
enzyme-loaded erythrocytes in in-vitro correction of arginase-deficient
erythrocytes in familial hyperargininemia. Clinical chemistry, 22(3), 323–326
26. Billah,
M. M., Finean, J. B., Coleman, R., & Michell, R. H. (1977). Permeability
characteristics of erythrocyte ghosts prepared under isoionic conditions by a
glycol-induced osmotic lysis. Biochimicaet biophysica acta, 465(3), 515–526.
https://doi.org/10.1016/0005-2736(77)90269-3
27. Rechsteiner
M. C. (1975). Uptake of proteins by red blood cells. Experimental cell
research, 93(2), 487–492. https://doi.org/10.1016/0014-4827(75)90478-4
28. Pitt,
E., Lewis, D. A., & Offord, R. E. (1983). The use of corticosteroids
encapsulated in erythrocytes in the treatment of adjuvant induced arthritis in
the rat. Biochemical pharmacology, 32(22), 3355–3358.
https://doi.org/10.1016/0006-2952(83)90362-3
29. AK
Shah, A Rambhade, A Ram, SKJ ain, Journal of chemical & pharmaceutical
research, 2011, 3(2).
30. AK
Shah, A Rambhade, A Ram, SKJ ain, Journal of chemical & pharmaceutical
research, 2011, 3(2).
31. Rajendra
Jangde, Asian J. Res. Pharm. Sci., 2011, 1(4), 83-92
32. D.A.
Lewis and H.O. Alpar, “Therapeutic Possibilities of Drugs Encapsulated in
Erythrocytes,” Int. J. Pharm. 22, 137–146 (1984).
33. S.
Jain and N.K. Jain, “Engineered Erythrocytes as a Drug Delivery System,” Indian
J. Pharm. Sci. 59, 275–281 (1997)
34. G.
Fiorelli et al., “Transfusion of Thalasemic Patients with Desferrioxamine
Loaded Standard RedBlood Cell Units,” Adv. Biosci. (series) 67, 47–54 (1987)
35. S.J.
Updike and R.T. Wakamiya, “Infusion of Red Blood Cell-Loaded Asparaginase in
Monkey,” J. Lab. Clin. Med. 101, 679–691 (1983).
36. H.O.
Alpar and D.A. Lewis,“Therapeutic Efficacy of Asparaginase Encapsulated in
Intact Erythrocytes,” Biochem. Pharmacol. 34, 257–261(1985).
37. M.P.
Summers, “Recent Advances in Drug Delivery,” Pharm. J. 230,643–645 (1983)
38. H.
Tajerzadeh and M. Hamidi, “Evaluation of the HypotonicPreswelling Method for
Encapsulation of Enalaprilat in Human Intact Erythrocytes,” Drug Dev. Ind.
Pharm. 26, 1247–1257 (2000)
39. J.
Bird, R. Best, and D.A. Lewis, “The Encapsulation of Insulin in Erythrocytes,”
J. Pharm. Pharmacol. 35, 246–247 (1983)
40. M.
Magnani et al., “Acetaldehyde Dehydrogenase-Loaded Erythrocytes as Bioreactors
for Removal of Blood Acetaldehyde, Alcoholism,”Clin. Exp. Res. 13, 849–859
(1989).118. G.W. Ihler et al., “Enzymatic Degradation of Uricase-Loaded Human
Erythrocytes,” J. Clin. Invest. 56, 595–602 (1975).
41. D.A.
Lewis and H.O. Alpar, “Therapeutic Possibilities of Drugs Encapsulated in
Erythrocytes,” Int. J. Pharm. 22, 137–146 (1984).
42. G.M.
Ihler,“Erythrocyte Carriers,”Pharmacol. Ther. 20, 151–169 (1983)
43. J.R.
Deloach and G.M. Ihler,“A Dialysis Procedure for Loading of Erythrocytes with
Enzymes and Lipids,” Biochim. Biophys. Acta. 496,136–145 (1977).
44. N.
Talwar and N.K. Jain, “Erythrocytes as Carriers of Metronidazole:
45. In-Vitro
Characterization,” Drug Dev. Ind. Pharm. 18, 1799–1812 (1992).
46. A.
Zanella etal,“Desferrioxamine Loading of Red Cells for Transfusion,”Adv.
Biosci. (series) 67,17–27 (1987).
47. G.
Fiorelli et al., “Transfusion of Thalasemic Patients with Desferrioxamine
Loaded Standard Red Blood Cell Units,” Adv. Biosci. (series) 67, 47–54 (1987).
48. D.A.
Lewis and J. Desai, “The Use of Animal Models in the Encapsulation of Drugs in
Erythrocytes,” Adv. Biosci. (series) 67, 213–222(1987).
49. S.J.
Updike, R.T. Wakarniya, and E.N. Lightfoot, “Asparaginase Entrapped in Red
Blood Cells: Action and Survival,” Science 193, 681–683(1976).
50. B.
Teisseire et al., “In Vivo Consequences of Rightward Shift of the Hemoglobin
Dissociation Curve,”Adv. Biosci. (1987).
51. A.
Zanella et al., “Desferrioxamine Loading of Red Cells for Transfusion,” Adv.
Biosci. (series) 67, 17–27 (1987).
52. J.
Way et al., “Encapsulation of Rhodanese by Mouse Carrier Erythrocytes,” Adv.
Biosci. (series) 67, 123–128 (1987).